![Early-stage hepatocellular carcinoma screening in patients with chronic hepatitis B in China: a cost–effectiveness analysis China China](https://clinicalvalue.com/wp-content/uploads/2024/03/China-1280x852.jpg)
Hepatitis
![Early-stage hepatocellular carcinoma screening in patients with chronic hepatitis B in China: a cost–effectiveness analysis China China](https://clinicalvalue.com/wp-content/uploads/2024/03/China-1280x852.jpg)
![Advancing Liver Health Ecosystem for Improve Patient Outcomes: A Hong Kong Perspective DSC00485 1 DSC00485 1](https://clinicalvalue.com/wp-content/uploads/2023/09/DSC00485-1-1280x755.jpg)
Advancing Liver Health Ecosystem for Improve Patient Outcomes: A Hong Kong Perspective
In this interview with Prof Yuen, Chief of Division of Gastroenterology and Hepatology in the University of Hong Kong, explore Hong Kong's current liver health ecosystem,…
READ MORE![Serum PIVKA-II and alpha-fetoprotein at virological remission predicts hepatocellular carcinoma in chronic hepatitis B related cirrhosis patient experiencing stomachache patient experiencing stomachache](https://clinicalvalue.com/wp-content/uploads/2023/04/patient-experiencing-stomachache-1280x720.jpg)
Serum PIVKA-II and alpha-fetoprotein at virological remission predicts hepatocellular carcinoma in chronic hepatitis B related cirrhosis
This study aimed to investigate the role of serum PIVKA-II and alpha-fetoprotein in predicting HCC and mortality in cirrhotic CHB patients at virological remission following NA…
READ MORE![APASL 2023 Taiwan Congress Report APASL congress report thumbnail APASL congress report thumbnail](https://clinicalvalue.com/wp-content/uploads/2023/05/APASL-congress-report-thumbnail-1280x720.jpg)
APASL 2023 Taiwan Congress Report
Catch up on the highlights of APASL 2023 with this congress report, covering session on hepatitis B, hepatitis C, hepatocellular carcinoma, and fatty liver disease.
READ MORE![Surveillance of Hepatocellular Cancer Among Hepatitis B and Cirrhosis Patients Using Protein Induced by Vitamin K Absence-II (PIVKA-II): A Cost-Utility Analysis for Hong Kong as an Example of Endemic Regions HCC surveillance HK HECON HCC surveillance HK HECON](https://clinicalvalue.com/wp-content/uploads/2023/03/HCC-surveillance-HK-HECON-1280x836.jpg)
Surveillance of Hepatocellular Cancer Among Hepatitis B and Cirrhosis Patients Using Protein Induced by Vitamin K Absence-II (PIVKA-II): A Cost-Utility Analysis for Hong Kong as an Example of Endemic Regions
This study evaluates the cost-effectiveness of serological tests or ultrasound alone versus their joint use with or without multivariate index algorithm for HCC screening in chronic…
READ MORE![Cost-effectiveness Analysis of GAAD algorithm on Hepatocellular Carcinoma Screening in Patients with Chronic Hepatitis B in China unnamed 3 unnamed 3](https://clinicalvalue.com/wp-content/uploads/2023/03/unnamed-3.png)
Cost-effectiveness Analysis of GAAD algorithm on Hepatocellular Carcinoma Screening in Patients with Chronic Hepatitis B in China
This study evaluates the cost-effectiveness of serological tests or ultrasound alone versus their joint use with or without multivariate index algorithm for HCC screening in chronic…
READ MORE![Diagnostic value of PIVKA-II and alpha-fetoprotein in hepatitis B virus-associated hepatocellular carcinoma Screenshot 2023 01 27 175200 Screenshot 2023 01 27 175200](https://clinicalvalue.com/wp-content/uploads/2023/03/Screenshot-2023-01-27-175200-1280x633.png)
Diagnostic value of PIVKA-II and alpha-fetoprotein in hepatitis B virus-associated hepatocellular carcinoma
This study aims to determine the cutoff values and to compare the diagnostic role of alpha-fetoprotein (AFP) and prothrombin induced by vitamin K absence-II (PIVKA-II) in…
READ MORE![Diagnostic value of prothrombin induced by the absence of vitamin K or antagonist-II (PIVKA-II) for early stage HBV related hepatocellular carcinoma model human liver made paper stethoscope model human liver made paper stethoscope](https://clinicalvalue.com/wp-content/uploads/2023/03/model-human-liver-made-paper-stethoscope-1280x880.jpg)
Diagnostic value of prothrombin induced by the absence of vitamin K or antagonist-II (PIVKA-II) for early stage HBV related hepatocellular carcinoma
This study aims to evaluate the diagnostic efficacy of prothrombin induced by the absence of vitamin K or antagonist-II (PIVKA-II) for early stage hepatitis virus B…
READ MORE![Diagnostic value of serum PIVKA-II levels for BCLC early hepatocellular carcinoma and correlation with HBV DNA doctor performing medical research lab doctor performing medical research lab](https://clinicalvalue.com/wp-content/uploads/2023/03/doctor-performing-medical-research-lab-1280x853.jpg)
Diagnostic value of serum PIVKA-II levels for BCLC early hepatocellular carcinoma and correlation with HBV DNA
This study aims to determine the clinical value of serum Prothrombin induced by vitamin K absence-II (PIVKA-II) in early hepatocellular carcinoma (HCC), and to explore its…
READ MORE![Liver Disease in Asia Pacific: Insights from Prof Pierce Chow Liver Disease in Asia Pacific Insights from Prof Pierce Chow Liver Disease in Asia Pacific Insights from Prof Pierce Chow](https://clinicalvalue.com/wp-content/uploads/2022/12/Liver-Disease-in-Asia-Pacific_-Insights-from-Prof-Pierce-Chow.jpg)
Liver Disease in Asia Pacific: Insights from Prof Pierce Chow
In this Q&A, Prof Pierce Chow of the National Cancer Centre Singapore discusses the epidemiology of liver disease in Asia Pacific; key considerations around the clinical…
READ MORE![Tackling HCV in Punjab: local experts share strategies for success Tackling HCV in Punjab local experts share strategies for success Tackling HCV in Punjab local experts share strategies for success](https://clinicalvalue.com/wp-content/uploads/2022/12/Tackling-HCV-in-Punjab_-local-experts-share-strategies-for-success.png)
Tackling HCV in Punjab: local experts share strategies for success
Punjab is one of Pakistan’s largest provinces and has a particularly high HCV prevalence rate of roughly 9%, compared to 5.4% for Pakistan’s total population. Hear…
READ MORE![Pakistan’s national HCV elimination programme: insights from Dr Huma Qureshi Pakistans national HCV elimination programme insights from Dr Huma Qureshi Pakistans national HCV elimination programme insights from Dr Huma Qureshi](https://clinicalvalue.com/wp-content/uploads/2022/12/Pakistans-national-HCV-elimination-programme_-insights-from-Dr-Huma-Qureshi.jpg)
Pakistan’s national HCV elimination programme: insights from Dr Huma Qureshi
In 2019, Pakistan announced a nationwide programme to scale up HCV prevention, testing and treatment. Hear from gastroenterologist Dr Huma Qureshi, a key figure in Pakistan’s…
READ MORE![Hepatitis C: the patient journey from screening to diagnosis and treatment Hepatitis C the patient journey from screening to diagnosis and treatment 1 Hepatitis C the patient journey from screening to diagnosis and treatment 1](https://clinicalvalue.com/wp-content/uploads/2022/12/Hepatitis-C_-the-patient-journey-from-screening-to-diagnosis-and-treatment-1.jpg)
Hepatitis C: the patient journey from screening to diagnosis and treatment
An estimated 71 million people around the world are chronically infected with hepatitis C virus (HCV), with a large proportion currently being undiagnosed or diagnosed late.…
READ MORE![HCV screening in Egypt: key elements of a successful national screening programme HCV screening in Egypt key elements of a successful national screening programme 1 HCV screening in Egypt key elements of a successful national screening programme 1](https://clinicalvalue.com/wp-content/uploads/2022/12/HCV-screening-in-Egypt_-key-elements-of-a-successful-national-screening-programme-1.jpg)
HCV screening in Egypt: key elements of a successful national screening programme
In 2018, the world’s largest HCV screening campaign was initiated in Egypt. Within 7 months following its initiation, 49.5 million people were screened; and 2.2 million…
READ MORE![HCV elimination in Sindh: insights from Prof Muhammad Sadik Memon and Dr Zaigham Abbas HCV screening in Egypt key elements of a successful national screening programme HCV screening in Egypt key elements of a successful national screening programme](https://clinicalvalue.com/wp-content/uploads/2022/12/HCV-screening-in-Egypt_-key-elements-of-a-successful-national-screening-programme.jpg)
HCV elimination in Sindh: insights from Prof Muhammad Sadik Memon and Dr Zaigham Abbas
The province of Sindh has one of the world’s highest rates of HCV infection and bears the second highest disease burden of both HBV and HCV…
READ MORE![HCV elimination in Pakistan: insights from Dr Zaigham Abbas HCV elimination in Pakistan insights from Dr Zaigham Abbas HCV elimination in Pakistan insights from Dr Zaigham Abbas](https://clinicalvalue.com/wp-content/uploads/2022/12/HCV-elimination-in-Pakistan_-insights-from-Dr-Zaigham-Abbas.jpg)
HCV elimination in Pakistan: insights from Dr Zaigham Abbas
Pakistan has one of the world’s highest rates of HCV infection. Learn from Dr Zaigham Abbas, Head of Gastroenterology at Ziauddin University Hospital and President of…
READ MORE![HCV elimination in Northern Pakistan: Prof Aamir Khan on treating patients in KPK province and the Afghan borderlands HCV elimination in Northern Pakistan Prof Aamir Khan on treating patients in KPK province and the Afghan borderlands HCV elimination in Northern Pakistan Prof Aamir Khan on treating patients in KPK province and the Afghan borderlands](https://clinicalvalue.com/wp-content/uploads/2022/12/HCV-elimination-in-Northern-Pakistan_-Prof-Aamir-Khan-on-treating-patients-in-KPK-province-and-the-Afghan-borderlands.jpg)
HCV elimination in Northern Pakistan: Prof Aamir Khan on treating patients in KPK province and the Afghan borderlands
Pakistan has one of the world’s highest rates of HCV infection. It's no surprise that their healthcare systems face mounting pressure from HCV-related conditions. Learn from…
READ MORE![Future therapies for chronic Hepatitis B and the role of diagnostics Future therapies for chronic Hepatitis B and the role of diagnostics Future therapies for chronic Hepatitis B and the role of diagnostics](https://clinicalvalue.com/wp-content/uploads/2022/12/Future-therapies-for-chronic-Hepatitis-B-and-the-role-of-diagnostics.jpg)
Future therapies for chronic Hepatitis B and the role of diagnostics
Hepatitis B is an important infectious disease problem in the APAC region. Learn from Prof Henry Chan, director of the Center for Liver Health at Chinese…
READ MORE